Paul Tudor Jones Cyma Bay Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$10.86 - $17.62 $268,991 - $436,429	24,769 New	24,769 $369,000
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $26,890 - $43,454	-21,512 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $28,610 - $127,566	21,512 New	21,512 $42,000
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $122,551 - $148,755	-15,978 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $95,069 - $131,978	15,978	15,978 $129,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.